Navigation Links
Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options
Date:7/25/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)...fix without losing taste, experts say , ,...t healthier this holiday season by altering recipe...he Texas AgriLife Extension Service. , Holiday...f almost any holiday recipe without a noticeable d...amowicz said in a news release. , "If a recipe...
(Date:11/21/2008)...ether to stop abusive behavior, experts say , ...or that was once dismissed as "kids being kids" is...research shows the negative effects on both the bu...chools, parents and even kids themselves are comin...vior. , "Bullying shouldn,t be considered a no...
(Date:11/21/2008)...Call/ -- Heska Corporation,(Nasdaq: HSKA ) toda...y of,Security Analysts, 12th Annual Biotech and S... 1177 Avenue of the Americas, 2nd Floor in New Yor...9:35 a.m. Eastern Time (7:35 a.m.,Mountain Time) ... weeks,following the presentation through a link ...
(Date:11/21/2008)...nique to combat cancer, study says, , ...earchers have discovered that some cancer cells us...might lead to new treatments that starve and kill ...cells in the body need to produce energy. They do ...quires oxygen. Compared with normal cells, tumor c...
Breaking Medicine News(10 mins):Health News:Substitutions Make Holiday Fare Healthier 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:New Approach Keeps Tumor Cells From Refueling 2
...he director general of the Uganda AIDS Commission,...y hamper patients’ reach of anti-retroviral drugs/...es. Presently almost 75,000 patients are using the...augment the annual healthcare budget over the year...
...to fight against bird flu was developed by Peter P...nai School of Medicine in New York City//. He said...g of birds. It is a vaccine for the poultry and it...astle disease. The team of American researchers in...
...omprising of senior doctors, members of the Scotti...re in San Francisco for up to a fortnight// at cos...tants. They are trying to recruit staff under a co...rtage of physicians. With hundreds of junior doct...
... nursing technology in India is very similar to th...anslated into the United States turning// towards ... also being rated high in the quality of training ...zing their dream of seeking greener pastures. St....
Other Medicine News:Health News:Plans Of Recruiting Pas From America Causes Displeasure In Scotland 2Health News:Plans Of Recruiting Pas From America Causes Displeasure In Scotland 3
(Date:11/20/2008)...IA, Nov. 20 GlaxoSmithKli...States Food and Drug Administration (FDA) granted ... for the treatment of thrombocytopenia in patients... purpura (ITP) who have had an insufficient respon...omy. The approval is a significant milestone for P...
(Date:11/20/2008)... 20 Arpida (SWX:,ARPN) ...sory Committee of the,U.S. Food and Drug Administ...al of intravenous iclaprim, an antibiotic currentl...th complicated skin and skin structure infections,...esistant Staphylococcus,aureus (MRSA). , A...
(Date:11/20/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI... the Phase 1B,clinical trial of their lead drug c...ZL101, at the Society for Integrative Oncology,s F.... The Company,s oral presentation was selected,a...a part of the Best of the,SIO Session on November...
(Date:11/20/2008)...ire/ -- Radius Health ("Radius") announced today t... second institutional financing round, increasing ... total amount raised since the company,s inception...estors participated in the financing, led by MPM B..., The Wellcome Trust, HealthCare Ventures, Oxford ...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 1SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 3AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 1AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 2AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 3Black Americans Still Wary of Clinical Trials 9519 1Black Americans Still Wary of Clinical Trials 9519 2Black Americans Still Wary of Clinical Trials 9519 3Black Americans Still Wary of Clinical Trials 9519 4Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 1Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 2Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 3
...ccine could offer protection,for infants against ...isease , , TORONTO, Canada, May 11, , 2007 ...rom a,Phase II vaccine clinical study presented th... (PAS) Annual Meeting in,Toronto, Canada. The new ... vaccine holds potential to protect infants in the...
...SINESS WIRE)--May 14, 2007 - BioDelivery,Sciences ...ional,statistically significant results with BEMA ... in its Phase III efficacy clinical,trial for the ...inuing analysis of the,secondary efficacy endpoint... SPID 15 (Summary of Pain Intensity Difference at,...
Other Medicine Technology:GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 2GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 3GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 4GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 5BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 2BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 4
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium.
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm
Straight Iris Scissors; ring handle; 28mm from mid screw to tip; sharp tips; Overall length 110; Also available in 100mm overall length; Stainless Steel
The SURPASS Perfusion Catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The SURPASS
Medicine Products: